# Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

> **NCT05520970** · PHASE2 · TERMINATED · sponsor: **Cellid Co., Ltd.** · enrollment: 4 (actual)

## Conditions studied

- COVID-19
- Vaccines

## Interventions

- **BIOLOGICAL:** AdCLD-CoV19-1

## Key facts

- **NCT ID:** NCT05520970
- **Lead sponsor:** Cellid Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-19
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study early terminated based on the sponsor(manufacture)'s decision
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05520970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05520970, "Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05520970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*